NA
BHVN

Neuburgh Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Neuburgh Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$155K Hold
3,706
– – ﹤0.01% 727
2019
Q2 		$162K Buy
3,706
+2,312
+166% +$130K 0.01% 727
2019
Q1 		$72K Hold
1,394
– – ﹤0.01% 826
2018
Q4 		$52K Buy
+1,394
New +$50.3K ﹤0.01% 830

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Neuburgh Advisers's BHVN Position: Q3 2019 in Review

Neuburgh Advisers held its Biohaven Pharmaceutical Holding Company Ltd. (BHVN) position steady in Q3 2019 at 3,706 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #727.

Neuburgh Advisers first reported a position in BHVN in Q4 2018 and has held it in 4 quarters since. The position peaked at $162K in Q2 2019. 184 funds tracked by Wall St. Rank hold BHVN as of Q3 2019.

  • Neuburgh Advisers held 3,706 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $155K as of Q3 2019.
  • Neuburgh Advisers left its Biohaven Pharmaceutical Holding Company Ltd. share count unchanged in Q3 2019.
  • Biohaven Pharmaceutical Holding Company Ltd. made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #727 holding.
  • Neuburgh Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $162K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.